Myriad Genetics Investigation: Bragar Eagel & Squire, P.C. Examines Potential Securities Laws Violations

Myriad Genetics, Inc., a leading molecular diagnostic company, has come under scrutiny following the announcement of its Q2 2026 financial results. The company reported revenue of approximately $190.7 million, a decline of roughly 11% year-over-year and below Wall Street consensus. This news has prompted Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, to launch an investigation into potential claims against Myriad Genetics.

The investigation, led by Bragar Eagel & Squire, P.C., will examine whether Myriad Genetics has violated federal securities laws and/or engaged in other unlawful business practices. This comes after the company cut its full-year 2026 revenue guidance to $770-$790 million, down from the previously announced $860-$880 million. Additionally, Myriad Genetics suspended its adjusted EBITDA guidance, which was initially set at $37-$49 million. Management attributed the shortfall to reimbursement pressure, collections issues, lower average revenue per test, and weaker prenatal performance.

Notably, Myriad Genetics had reiterated its full-year 2026 revenue guidance of $860-$880 million as recently as May 5, 2026. The decision to slash this guidance by approximately $90 million just three months later has raised concerns among investors. The sudden change in revenue guidance and the suspension of adjusted EBITDA guidance have contributed to a decline in the company's stock price.

Investors who have suffered losses in Myriad Genetics are urged to contact Bragar Eagel & Squire, P.C. to discuss their options. The law firm is encouraging investors to reach out to Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648. There is no cost or obligation to investors who wish to participate in the action.

Bragar Eagel & Squire, P.C. is a renowned law firm with offices in New York, South Carolina, and California. The firm has a nationwide practice and has handled numerous cases in federal and state courts. With a strong track record of representing individual and institutional investors in securities, derivative, and commercial litigation, Bragar Eagel & Squire, P.C. is well-equipped to take on this investigation.

As the investigation unfolds, it will be crucial for investors to stay informed about the latest developments. Myriad Genetics' financial performance and the outcome of the investigation will likely have significant implications for the company's stock price and the broader molecular diagnostic industry. Investors can follow Brandon Walker, Esq. on LinkedIn for updates and information about the case.

In conclusion, the investigation into Myriad Genetics by Bragar Eagel & Squire, P.C. is a significant development for investors who have suffered losses in the company. As the investigation continues, it is essential for investors to understand their rights and options. By contacting Bragar Eagel & Squire, P.C., investors can take the first step towards seeking justice and recovering their losses.